11 C-JHU 75528 : A Radiotracer for PET Imaging of CB 1 Cannabinoid Receptors

The development of the radioligands for PET imaging of the cerebral cannabinoid receptor (CB1) is of great importance for studying its role in neuropsychiatric disorders, obesity, and drug dependence. None of the currently available radioligands for CB1 are suitable for quantitative PET, primarily because of their insufficient binding potential (BP) in brain or low penetration through the blood–brain barrier (BBB). The goal of this study was to evaluate 11C-JHU75528, an analog of the selective CB1 antagonist rimonabant, in vivo as a potential CB1 radioligand for PET. Methods: The brain regional distribution and pharmacology of 11C-JHU75528 have been evaluated in vivo in mice (dissection) and baboons (PET). Results: 11C-JHU75528 readily entered the mouse and baboon brain and specifically and selectively labeled cerebral CB1 receptors. The ratio of striatum to brain stem in mice and the binding potential (BP) in the baboon putamen were 3.4 and 1.321.5, respectively. The specific binding of 11C-JHU75528 in vivo was blocked by preinjection of nonlabeled JHU75528. Administration of rimonabant (1 mg/kg, intravenously) also blocked the specific binding of 11C-JHU75528 in the mouse and baboon brain, whereas various central noncannabinoid drugs did not significantly reduce the 11C-JHU75528 binding in the mouse brain. 11C-JHU75528 formed several hydrophilic metabolites, but only a minute fraction of metabolic radioactivity penetrated the BBB.Conclusion: 11C-JHU75528 holds promise as a radiotracer with suitable imaging properties for quantification of CB1 receptors in the human brain.

[1]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[2]  A. Makriyannis,et al.  Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. , 2005, Nuclear medicine and biology.

[3]  G. Kennett,et al.  Cannabinoids and the regulation of ingestive behaviour. , 2005, Current drug targets.

[4]  P. Casellas,et al.  Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. , 1999, Life sciences.

[5]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Pertwee.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids , 2005, The AAPS Journal.

[7]  R. Laufer,et al.  Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. , 2003, European journal of biochemistry.

[8]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[9]  A. Horti,et al.  Synthesis of N‐(piperidin‐1‐yl)‐5‐(4‐methoxyphenyl)‐1‐(2‐chlorophenyl)‐4‐[18F]fluoro‐1H‐pyrazole‐3‐carboxamide by nucleophilic [18F] fluorination: a PET radiotracer for studying CB1 cannabinoid receptors , 2003 .

[10]  A. Wolf,et al.  PET studies in the primate brain and biodistribution in mice using (−)-5′-18 F-Δ 8-THC , 1991, Pharmacology Biochemistry and Behavior.

[11]  A. Horti,et al.  Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. , 2005, Journal of medicinal chemistry.

[12]  A. Rissanen,et al.  Preventive cardiologyAbstractEffects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience From the RIO-Europe Study , 2005 .

[13]  V. Arango,et al.  Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims , 2005, Biological Psychiatry.

[14]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[15]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[16]  V. Arango,et al.  Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims , 2004, Molecular Psychiatry.

[17]  R. Dannals,et al.  Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. , 2000, Nuclear medicine and biology.

[18]  E. Tzavara,et al.  A role for cannabinoid CB1 receptors in mood and anxiety disorders , 2005, Behavioural pharmacology.

[19]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[20]  Mark Slifstein,et al.  Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[21]  H. Ujike,et al.  New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. , 2004, Journal of pharmacological sciences.

[22]  Therese Garrick,et al.  Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  A. Schoffelmeer,et al.  Cannabinoid CB1 receptors control conditioned drug seeking. , 2005, Trends in pharmacological sciences.

[24]  J. Herbert,et al.  Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. , 2002, Nuclear medicine and biology.

[25]  R. Dannals,et al.  Synthesis of [18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors , 1999 .

[26]  Alan C. Evans,et al.  Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  D. Wong,et al.  Column-switching HPLC for the analysis of plasma in PET imaging studies. , 2000, Nuclear medicine and biology.

[28]  S. Goldberg,et al.  Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. , 2005, Trends in pharmacological sciences.

[29]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  F. Ferro,et al.  Cannabinoid Receptors and Their Relationships with Neuropsychiatric Disorders , 2005, International journal of immunopathology and pharmacology.

[31]  A. Hoffman,et al.  Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.

[32]  A. Horti,et al.  Regioselective F‐18 radiolabeling of AM694, a CB1 cannabinoid receptor ligand , 2003 .

[33]  D. Wong,et al.  In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 , 1993, Synapse.

[34]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[35]  Payton King,et al.  Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo , 1998, Journal of neurochemistry.

[36]  R. Buchert,et al.  [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients , 2004, Biological Psychiatry.